VERAXA Biotech (NASDAQ: VRXA), an emerging leader in designing novel cancer therapies, presented its first in vivo proof-of-concept data and additional in vitro findings validating its BiTAC-ADC technology platform at the 17th World ADC Congress in San Diego. The in vivo study demonstrated significant tumor regression in a breast cancer model following a single 3 mg/kg dose, with no observed decrease in body weight. The results also showed that both BiTAC-ADC components were required to produce the intended tumor-specific response.
Additional in vitro studies demonstrated the platform's ability to distinguish cancer cells from healthy cells, prevent the release of active toxins outside the tumor and target multiple cancer cell lines. The findings support the potential of BiTAC-ADCs to deliver efficacy comparable to conventional antibody-drug conjugates while offering a differentiated safety profile designed to reduce systemic toxicity.
The data comes as the company advances its pipeline of antibody-based therapeutics, including bispecific T cell engagers and bispecific ADCs. To view the full press release, visit https://ibn.fm/cs8SW. For more details on VERAXA Biotech, see VERAXA Biotech (NASDAQ: VRXA). The latest news and updates relating to VRXA are available in the company's newsroom at https://ibn.fm/VRXA.
This news is important because it represents a potential step forward in cancer treatment. Conventional ADCs, while effective, often cause systemic toxicity due to premature release of cytotoxic payloads outside tumor cells. VERAXA's BiTAC-ADC platform appears to address this by requiring both components to bind for activity, which may limit damage to healthy tissues. If the preclinical results translate into clinical benefit, BiTAC-ADCs could offer patients a safer and more tolerable treatment option, potentially expanding the therapeutic window and improving outcomes.
For the biotech industry, the data validates a novel approach to ADC design and could spur further investment in bispecific antibody technologies. VERAXA, founded on breakthroughs from the European Molecular Biology Laboratory, is positioning itself as a key player in next-generation antibody therapeutics. As the company moves toward clinical development, the results will be closely watched by investors and researchers alike.
